circRNA sequencing-Illumina
Astaamaha
● Qalafsanaanta rRNA oo ay ku xigto diyaarinta maktabadda jihada, taasoo awood u siinaysa xogta isku xigxiga ee u gaarka ah.
● Socod-shaqeedka bioinformatic wuxuu awood u siinayaa saadaasha circRNA iyo cabbirka muujinta
Faa'iidooyinka Adeegga
●Maktabadaha RNA oo dhamaystiran:Waxaan isticmaalnaa dhimista rRNA halkii aan ka isticmaali lahayn dhimista RNA toosan diyaarintayada maktabadda ka hor, hubinta in xogta taxanaha ah ay ku jiraan kaliya maahan circRNA laakiin sidoo kale mRNA iyo lncRNA, taas oo awood u siinaysa falanqaynta wadajirka ah ee xogtan
●Falanqaynta ikhtiyaariga ah ee shabakadaha RNA (ceRNA) ee tartanka ku jira: bixinta aragti qoto dheer oo ku saabsan hababka nidaaminta gacanta
●Khibrad Balaadhan: iyada oo leh rikoodh raad-raac ah oo lagu farsameeyo in ka badan 20,000 oo muunado BMK ah, oo ku baahsan noocyo kala duwan oo muunado iyo mashruucyo lncRNA ah, kooxdeenu waxay u keentaa khibrad badan mashruuc kasta.
●Xakamaynta tayada adagWaxaan hirgelineynaa qodobbada kontoroolka asaasiga ah ee dhammaan heerarka, laga bilaabo muunad iyo diyaarinta maktabadda ilaa isku xigxiga iyo bioinformatics.Kormeerkan taxaddar leh wuxuu xaqiijinayaa gaarsiinta natiijooyin tayo sare leh oo joogto ah.
● Taageerada iibka kadibBallanqaadkayaga waxa uu dhaafsiisan yahay dhamaystirka mashruuca oo leh 3 bilood oo adeega iibka kadib.Inta lagu jiro wakhtigan, waxaan bixinaa dabagalka mashruuca, caawinta cilad-raadinta, iyo fadhiyada Q&A si wax looga qabto su'aalo kasta oo la xidhiidha natiijooyinka.
Tusaalaha Shuruudaha iyo Bixinta
| Maktabadda | Platform | Xogta lagu taliyay | Xogta QC |
| Poly A waa la hodmay | Illumina PE150 | 16-20 Gb | Q30≥85% |
Tusaalaha Shuruudaha:
Nucleotides:
| Conc.(ng/μl) | Qadarka (μg) | daahirnimo | Daacadnimo |
| ≥ 100 | ≥ 0.5 | OD260/280=1.7-2.5 OD260/230=0.5-2.5 Xaddidan ama aan lahayn borotiin ama wasakh DNA oo lagu muujiyey jel. | Dhirta: RIN≥6.5; Xoolaha: RIN≥7.0; 5.0≥28S/18S≥1.0; xaddidan ama aan lahayn sare u qaadis aasaasi ah |
● Dhirta:
Xididka, stem ama Petal: 450 mg
Caleen ama abuur: 300 mg
Miraha: 1.2 g
● Xoolaha:
Wadnaha ama mindhicirka: 450 mg
Viscera ama Maskaxda: 240 mg
Murqaha: 600 mg
Lafaha, timaha ama maqaarka: 1.5g
● Arthropods:
Cayayaanka: 9g
Crustacea: 450 mg
● Dhiig dhan:2 tuubbo
Unugyada: 106 unugyo
● Serum iyo Plasma: 6 ml
Tusaalaha keenista lagu taliyay
Weel: 2 ml oo tuubo sentrifuge ah (Faylada qasacadaysan laguma talinayo)
Tusaalaha calaamadaynta: Kooxda+ku celcelinta tusaale A1, A2, A3;B1, B2, B3......
Raritaanka:
1. Barafka qallalan: Muunadodu waxay u baahan yihiin in lagu xidho bac oo lagu aaso baraf qallalan.
2. Tuubooyinka RNAstable: Muunada RNA waxaa lagu qallajin karaa tuubada xasilinta RNA (tusaale RNAstable®) waxaana lagu rari karaa heerkulka qolka.
Socodka Shaqada Adeegga
Naqshadaynta tijaabada
Tusaalaha keenista
soo saarida RNA
Dhismaha maktabadda
Isku xigxiga
Falanqaynta xogta
Adeegyada iibka kadib
Bioinformatics
saadaasha circRNA: qaybinta koromosoomyada
circRNA-yada si ka duwan loo soo bandhigay - Dhulkaanaha
Si ka duwan loo soo bandhigay circRNA-yada - kooxaynta kala sareynta
Kobcinta shaqaynta ee hiddo-wadaha martida loo yahay ee circRNA
Sahami horumarka cilmi-baarista ee ay fududeeyeen adeegyada isku xigxiga ee BMKGene' circRNA iyada oo loo marayo ururinta daabacaadyo la soo xulay.
Wang, X. iyo al.(2021) 'CPSF4 waxay xakameysaa samaynta circRNA iyo microRNA dhexdhexaadinta hiddo-wadaha aamusnaanta hepatocellular carcinoma', Oncogene 2021 40:25, 40(25), bogga. 4338-4351.doi: 10.1038/s41388-021-01867-6.
Xia, K. iyo al.(2023) 'X oo-jawaab qoraal ah ayaa daaha ka qaadaya doorka wareegtada RNA133 ee u adkeysiga cudurrada iyadoo la xakameynayo muujinta OsARAB ee bariiska', Cilmi-baarista Phytopathology, 5(1), bogga 1-14.doi: 10.1186/S42483-023-00188-8/SAWIRRO/6.
Y, H. iyo al.(2023) 'CPSF3 waxay beddeshaa dheelitirka qoraallada wareegta ah iyo kuwa toosan ee kansarka hepatocellular.doi: 10.21203/RS.3.RS-2418311/V1.
Zhang, Y. iyo al.(2023) 'Qiimayn dhamaystiran oo cirrno ah oo ku jira cirrhotic cardiomyopathy ka hor iyo ka dib beerka bedelka', International Immunopharmacology, 114, p.109495. doi: 10.1016/J.INTIMP.2022.109495.
